Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Abeona Therapeutics (ABEO) over the last 14 years, with Q3 2025 value amounting to $901000.0.

  • Abeona Therapeutics' Interest Expenses fell 1823.96% to $901000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 2173.11%. This contributed to the annual value of $4.2 million for FY2024, which is 90669.86% up from last year.
  • Latest data reveals that Abeona Therapeutics reported Interest Expenses of $901000.0 as of Q3 2025, which was down 1823.96% from $957000.0 recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Interest Expenses registered a high of $1.5 million during Q2 2021, and its lowest value of $53000.0 during Q4 2021.
  • Over the past 5 years, Abeona Therapeutics' median Interest Expenses value was $683000.0 (recorded in 2021), while the average stood at $624947.4.
  • As far as peak fluctuations go, Abeona Therapeutics' Interest Expenses tumbled by 9618.16% in 2021, and later surged by 94952.38% in 2024.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Interest Expenses stood at $53000.0 in 2021, then skyrocketed by 235.85% to $178000.0 in 2022, then tumbled by 38.76% to $109000.0 in 2023, then soared by 892.66% to $1.1 million in 2024, then fell by 16.73% to $901000.0 in 2025.
  • Its Interest Expenses was $901000.0 in Q3 2025, compared to $957000.0 in Q2 2025 and $998000.0 in Q1 2025.